F. Hoffmann-La Roche Ltd: Roche Annual General Meeting 2021
Christoph Franz re-elected as Chairman of the Board of Directors; all current Board members re-elected
34th consecutive dividend increase to CHF 9.10 per share
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). Owing to the pandemic restrictions, the AGM was held with only those persons required by the Articles of Incorporation in attendance and with no shareholders physically present. Roche shareholders were able to exercise their rights via written or electronically submitted instructions to the independent proxy, Testaris AG. The independent proxy represented 84.58% of the total of 160,000,000 shares. The Management Report, the Annual Financial Statements and the Consolidated Financial Statements for 2020 were approved.
Search jobs 03-Feb-2021 Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
NEW YORK (BUSINESS WIRE) Bristol Myers Squibb (NYSE: BMY) and The Rockefeller University today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has been granted a global exclusive license to develop, manufacture and commercialize Rockefeller’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19.
Despite the increasing availability of the vaccines, there will continue to be patients who contract COVID-19 and will need treatment for their infection. This novel treatment is a combination of two mAbs directed at blocking the SARS-CoV-2 spike protein and neutralizing the virus. The mAbs have been engineered to be highly potent a
Bristol Myers Squibb (BMS) and The Rockefeller University announced on February 3, 2021, that they have entered into a definitive agreement under which BMS has been granted a global exclusive license to develop, manufacture, and commercialize Rockefeller’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the
Replies(2)
The $9 million grant to Rockefeller University will help it convert existing research labs on its Upper East Side campus into a new incubator for life-science companies. (Shutterstock / John Penney)
UPPER EAST SIDE, NY Rockefeller University will build a new life-sciences hub on its Upper East Side campus as part of a citywide push to make New York the public health capital of the world, Mayor Bill de Blasio announced Thursday.
The $9 million grant to Rockefeller will help it convert some of its existing academic research labs into a new incubator for life-science companies, dubbed the Tri-Institutional Translational Center for Therapeutics.
Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
Bristol Myers Squibb and The Rockefeller University today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has been granted a global exclusive license to develop, manufacture and commercialize Rockefeller’s novel monoclonal antibody duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19. Despite the increasing availability of the … Bristol Myers Squibb (NYSE: BMY) and The Rockefeller University today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has been granted a global exclusive license to develop, manufacture and commercialize Rockefeller’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19.